Bicycle Therapeutics (BCYC) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicycle Therapeutics (BCYC) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 53.4% versus a loss of 60.3%. Over five years, FULC leads with a -85.9% price change compared with -93.7% for BCYC. Fulcrum Therapeutics is the larger company by market cap ($280.0 million vs $261.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | FULC |
|---|---|---|
| Share price | $3.73 | $3.67 |
| Market cap | $261.07M | $280.01M |
| 1-day change | -1.58% | -0.54% |
| YTD return | -47.32% | -67.55% |
| 1-year return | -53.37% | -60.28% |
| 5-year return | -93.71% | -85.88% |
| EPS (TTM) | $-2.73 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $15.74 |
| 52-week low | $3.33 | $2.83 |
| Distance from 52-week high | -59.28% | -76.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +154.69% | 0.00% |
| Average volume | 391.03K | 1.53M |
| Shares outstanding | 50.55M | 76.30M |
| Employees | 288 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BCYC vs FULC FAQ
Which is bigger, Bicycle Therapeutics or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $280.01M compared with $261.07M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or FULC?
BCYC returned -53.37% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.